Patents by Inventor Christopher Lamarque

Christopher Lamarque has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucose Uptake Inhibitors
    Publication number: 20240360085
    Abstract: This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUT3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.
    Type: Application
    Filed: May 23, 2024
    Publication date: October 31, 2024
    Applicant: Kadmon Corporation, LLC
    Inventors: Kevin G. Liu, Kellen Olszewski, Ji-In Kim, Masha V. Poyurovsky, Koi Morris, Xuemei Yu, Christophe Lamarque
  • Glucose uptake inhibitors
    Patent number: 12030857
    Abstract: This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: July 9, 2024
    Assignee: Kadmon Corporation, LLC
    Inventors: Kevin G. Liu, Kellen L. Olszewski, Ji-In Kim, Masha V. Poyurovsky, Koi Morris, Xuemei Yu, Christophe Lamarque
  • ALLOSTERIC MODULATORS OF THE MU OPIOID RECEPTOR
    Publication number: 20220401430
    Abstract: Disclosed herein are compounds, of the class of amine-bearing heterocycles, which act as positive allosteric modulators and silent allosteric modulators of the mu opioid receptor. These compounds are useful for the treatment of pain, drug addiction, and other CNS derived maladies that are controlled directly or indirectly by activation of the mu opioid receptor. Methods for making and using the allosteric modulators disclosed herein are also provided.
    Type: Application
    Filed: July 16, 2021
    Publication date: December 22, 2022
    Inventors: Joel Francis Austin, Michael David VanHeyst, James S. Harvey, Elizabeth Gerig Rowley, Christophe Lamarque-Lacoste
  • Glucose Uptake Inhibitors
    Publication number: 20220363648
    Abstract: This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.
    Type: Application
    Filed: June 25, 2019
    Publication date: November 17, 2022
    Inventors: Kevin G. Liu, Kellen L. Olszewski, Ji-in Kim, Masha V. Poyurovsky, Koi Morris, Xuemei Yu, Christopher Lamarque
  • Allosteric modulators of the mu opioid receptor
    Patent number: 11071731
    Abstract: Disclosed herein are compounds, of the class of amine-bearing heterocycles, which act as positive allosteric modulators and silent allosteric modulators of the mu opioid receptor. These compounds are useful for the treatment of pain, drug addiction, and other CNS derived maladies that are controlled directly or indirectly by activation of the mu opioid receptor. Methods for making and using the allosteric modulators disclosed herein are also provided.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: July 27, 2021
    Assignee: Chiromics, LLC
    Inventors: Joel Francis Austin, Michael David VanHeyst, James S. Harvey, Elizabeth Gerig Rowley, Christophe Lamarque-Lacoste
  • Allosteric Modulators of the Mu Opioid Receptor
    Publication number: 20200276177
    Abstract: Disclosed herein are compounds, of the class of amine-bearing heterocycles, which act as positive allosteric modulators and silent allosteric modulators of the mu opioid receptor. These compounds are useful for the treatment of pain, drug addiction, and other CNS derived maladies that are controlled directly or indirectly by activation of the mu opioid receptor. Methods for making and using the allosteric modulators disclosed herein are also provided.
    Type: Application
    Filed: February 26, 2020
    Publication date: September 3, 2020
    Applicant: Chiromics, LLC
    Inventors: Joel Francis Austin, Michael David VanHeyst, James S. Harvey, Elizabeth Gerig Rowley, Christophe Lamarque-Lacoste
  • Allosteric modulators of the mu opioid receptor
    Patent number: 10603313
    Abstract: Disclosed herein are compounds, of the class of amine-bearing heterocycles, which act as positive allosteric modulators and silent allosteric modulators of the mu opioid receptor. These compounds are useful for the treatment of pain, drug addiction, and other CNS derived maladies that are controlled directly or indirectly by activation of the mu opioid receptor. Methods for making and using the allosteric modulators disclosed herein are also provided.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: March 31, 2020
    Assignee: CHIROMICS, LLC
    Inventors: Joel Francis Austin, Michael David VanHeyst, James S. Harvey, Elizabeth Gerig Rowley, Christophe Lamarque-Lacoste
  • Allosteric Modulators of the Mu Opioid Receptor
    Publication number: 20190030020
    Abstract: Disclosed herein are compounds which act as positive allosteric modulators and silent allosteric modulators of the mu opioid receptor. Methods for making and using the allosteric modulators disclosed herein are also provided.
    Type: Application
    Filed: July 27, 2018
    Publication date: January 31, 2019
    Applicant: Chiromics, LLC
    Inventors: Joel Francis Austin, Michael David VanHeyst, James S. Harvey, Elizabeth Gerig Rowley, Christophe Lamarque-Lacoste